Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Acalabrutinib and AZD9150 combination for the treatment of R/R DLBCL

In this video, Mark Roschewski, MD, National Cancer Institute, Bethesda, MD, reports on the results from one of the arms of the Phase I master protocol PRISM study (NCT03527147), which aimed to evaluate the combination of acalabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, and AZD9150, a STAT-3 inhibitor, in patients with relapsed and/or refractory diffuse large B-cell lymphoma (R/R DLBCL). Dr Roschewski first explains the basis of the study and the activity seen in acalabrutinib monotherapy, and then discusses the results observed when combining AZD9150 with acalabrutinib. This interview was filmed at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, 2021.